Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Sara Beygi"'
Autor:
Vishnu Shankar, Ash A. Alizadeh, Alyssa M. Kanegai, Debra K. Czerwinski, Neel K. Gupta, Joseph G Schroers-Martin, David M. Kurtz, Gladys M. Rodriguez, Lauren S. Maeda, Michael S. Khodadoust, Sara Beygi, Tanaya Shree, Ranjana H. Advani, Ronald Levy, Karen S. Corbelli, Etelka Gabriel
Publikováno v:
Blood
Background: Patients with B-cell lymphoma have poor clinical outcomes to SARS-CoV-2 infection (COVID-19) and are also more likely to have suboptimal responses to immunization. An understanding of which lymphoma patients are at greatest risk of poor C
Publikováno v:
Blood. 138:1325-1325
Background: Mogamulizumab is a humanized anti-CCR4 antibody approved for the treatment of mycosis fungoides and Sézary Syndrome. Despite almost universal expression of CCR4 in these diseases, many patients eventually develop resistance to mogamulizu
Autor:
Sara Beygi, Matthew J. Frank, Michael S. Khodadoust, Richard T. Hoppe, Hanlee P. Ji, Tanaya Shree, Ronald Levy, Sarah Haebe, Grady Day, Brock A. Martin, Anuja Sathe, Steven R. Long, Debra K. Czerwinski
Publikováno v:
Blood. 138:3539-3539
Introduction: In situ vaccination aims to induce an immune response locally at one tumor site that propagates systemically to all tumor sites. This approach can be effective in indolent lymphoma (Brody et al., JCO 2010, Frank et al., Cancer Discov 20
Autor:
Michael S. Khodadoust, Sara Beygi, Debra K. Czerwinski, Ronald Levy, Steven R. Long, Matthew J. Frank, Tanaya Shree, Brock A. Martin
Publikováno v:
Blood. 136:48-48
Introduction: Local treatment with intratumoral CpG (a toll-like receptor 9 agonist, SD-101) and low-dose radiation can elicit antitumor immune responses and global tumor reduction in patients with low-grade lymphoma (Frank, Cancer Discov, 2018). Ibr